HealiusASX:HLS +1.39%53 Days Payable is 259.06 as of Dec. 2025, which is 21% below its 10-year median of 328.52. GuruFocus rates ASX:HLS with a GF Score™ of 53/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Healius ranks better than 84.29% on this metric.
Healius's average Accounts Payable for the
six
months ended in Dec. 2025 was A$151 Mil. Healius's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$106 Mil.
Hence, Healius's Days Payable for the
six
months ended in Dec. 2025 was 259.06.
The historical rank and industry rank for Healius's Days Payable or its related term are showing as below:
ASX:HLS'
s Days Payable Range Over the Past 10 Years
Min: 216.38 Med: 328.52 Max: 389.04
Current: 275.83
During the past 13 years, Healius's highest Days Payable was 389.04. The lowest was 216.38. And the median was 328.52.
ASX:HLS's Days Payable is ranked better than 84.29% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs ASX:HLS: 275.83
Healius's Days Payable
declined
from Dec. 2024 (321.95) to Dec. 2025 (259.06).
It may suggest that Healiusaccelerated paying its suppliers.
Healius Days Payable Related Terms
Healius Days Payable Historical Data
* Premium members only.
The historical data trend for Healius's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HLS vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Healius's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healius Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Healius's Days Payable distribution charts can be found below:
* The bar in red indicates where Healius's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Healius's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healius (ASX:HLS) has a Days Payable of 259.06 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Healius and its competitors. This is 21% below median its historical median of 328.52. Over the past decade, Healius' Days Payable has ranged from 216.38 to 389.04. According to the industry distribution chart, Healius ranks #30 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 15.7%.
Is Healius' Days Payable too high?
Healius' current Days Payable of 259.06 is 21% below median its 10-year median of 328.52. Over the past 10 years, this metric has ranged from a low of 216.38 to a high of 389.04. The Medical Diagnostics & Research industry median Days Payable is 68.87. Healius' value of 259.06 is 276.2% above this industry median. Based on the distribution chart, Healius ranks #30 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Healius has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #30 out of 191 companies for Days Payable. This places Healius in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.87. Healius' value of 259.06 is 276.2% above this benchmark. Historically, Healius' own Days Payable has ranged from 216.38 to 389.04 over the past decade. While the company's 10-year median is 328.52 vs. the industry median of 68.87, Healius has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healius's current Days Payable of 259.06 is 276.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Healius and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healius's current Days Payable is 259.06, which is 21% below median its own 10-year median of 328.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.9% below its estimated fair value. The current Days Payable is 259.06, which is 21% below median its 10-year median of 328.52 and 276.2% above the Medical Diagnostics & Research industry median of 68.87. Healius' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Healius (ASX:HLS), the current Days Payable is 259.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healius (ASX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, Healius stock appears to be undervalued.
The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01.
GuruFocus considers Healius to be Possible Value Trap.
Key valuation signals for ASX:HLS:
Days Payable: 259.06 (21% below median its 10-year median of 328.52)
GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
Industry Position: 276.2% above the Medical Diagnostics & Research median (#30 of 191)
No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
53GF Score
Get the complete analysis for ASX:HLS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HLS has been successfully added to your 
